TAK-721 FDA Approval Status
TAK-721 (budesonide oral suspension) is a novel mucoadherent topically active oral viscous formulation of budesonide in development as a treatment for eosinophilic esophagitis (EoE).
Development Timeline for TAK-721
|Dec 15, 2020||U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.